Wire · opportunities
GC Biopharma Gets Phase 2 Approval for COVID-19 Vaccine
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 September 2026 · Fusion42 review
GC Biopharma received approval from South Korea's Ministry of Food and Drug Safety to begin a Phase 2 clinical trial for its mRNA COVID-19 vaccine candidate GC4006A, with plans for first patient dosing by year-end and a Phase 3 IND submission next year.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
South Korea's fast approval of GC Biopharma's Phase 2 COVID-19 vaccine trial opens a window to accelerate local mRNA vaccine development and production. If you build vaccine platforms or regional supply chains, the Korean market now offers a real-time clinical testbed and regulatory pathway.
◆ Coverage
1 source · 13 Sep 2026
◆ Related on Wire
◆ Topics